Skip to main content
Fig. 1 | BMC Medicine

Fig. 1

From: A new histone deacetylase inhibitor remodels the tumor microenvironment by deletion of polymorphonuclear myeloid-derived suppressor cells and sensitizes prostate cancer to immunotherapy

Fig. 1

Compared to the classical HDAC inhibitors SAHA and entinostat, CN133 had higher HDAC 1, 2, and 3 enzyme selective inhibition and prostate tissue targeting. A In vitro enzyme inhibition activity experiments confirmed that the inhibitory efficiency of HDACs 1, 2, and 3 was significantly higher than that of SAHA and entinostat. B LC–MS/MS was applicated to detect drug concentrations in plasma and prostate tissues of mice at eight time points including 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, and 24 h. CN133 was found to be lower than entinostat in plasma on average but higher than SAHA in plasma on average. C, D Drug concentration of average value (C) and two time points (1 h and 24 h, respectively) (D) in the prostate tissue were significantly higher than entinostat and SAHA

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us